CNR1 and metabolic syndrome: Nevertheless, strategies targeting the peripheral actions of EC still hold promise for the management of MetS, being devoid of the adverse central actions of the CB1 reverse-agonists7,9, but the precise role for of CB2 in mediating the metabolic actions of EC remains unclear.